Cytogen cancer, diagnostics/imaging news

CYTO ceased operations at its Cellcor Inc. subsidiary, which was developing its autologous lymphocyte therapy (ALT) to treat metastatic renal cell carcinoma. CYTO had been in discussions concerning e...